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Probiotics have been demonstrated to be useful to enhance gut health and prevent
gastrointestinal infections. The objective of this study is to demonstrate the potential
of the probiotic strain Bifidobacterium longum subsp. infantis CECT 7210 (B. infantis
IM1) to prevent and fight intestinal disease by using a Salmonella Typhimurium (Trial
1) or an enterotoxigenic Escherichia coli K88 (Trial 2) oral challenge in a weaning
piglet model. Seventy-two piglets were used in each trial. After an adaptation period,
animals were orally challenged. One animal per pen was euthanized at Days 4 and
8/9 (Trial 1/Trial 2) post-inoculation (PI). Animal performance, clinical signs, pathogen
excretion, fermentation, immune response, and intestinal morphology were evaluated. In
Trial 1, most parameters responded to the challenge, whereas, in Trial 2, effects were
much milder. Consistent effects of the probiotic were detected in both experiments:
Reduction of pathogen excretion (P = 0.043 on Day 3 PI, Trial 1) or ileal colonization
(33% reduction of animals with countable coliforms; P = 0.077, Trial 2); increases in
intraepithelial lymphocytes (P = 0.002 on Day 8 PI in Trial 1, P = 0.091 on Day 4 PI
in Trial 2), and improvement of the fermentation profile by increasing butyric acid in
non-challenged animals [P challenge × probiotic (interaction) = 0.092 in Trial 1 and P
= 0.056 in Trial 2] concomitant with an enhancement of the villus:crypt ratio on Day
8/9 PI (P interaction = 0.091 for Trial 1 and P = 0.006 for Trial 2). Challenged animals
treated with the probiotic showed reduced feed intakes (P interaction = 0.019 in Trial
1 and P = 0.020 in Trial 2) and had lower short-chain fatty acid concentrations in
the colon (P interaction = 0.008 in Trial 1 and P = 0.082 in Trial 2). In conclusion,
this probiotic demonstrated potential to reduce the intestinal colonization by pathogens
and to stimulate local immune response. However, effects on feed intake, microbial
fermentation, and intestinal architecture showed a differential pattern between challenged
and non-challenged animals. Effects of the probiotic intervention were dependent on the
structure of the ecosystem in which it was applied.
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INTRODUCTION
Gastroenteritis due to enteric infections occur globally each year,
and enterotoxigenic Escherichia coli spp. (ETEC) and Salmonella
spp. are among the most common bacterial causes of diarrhea-
associated morbidity and mortality (CDC, 2013; Lanata et al.,
2013), especially in children up to 5 years of age (Payment,
2002; Liu et al., 2012; Kotloff et al., 2013). The estimated annual
mortality from illness due to Salmonella spp., considering the
global population, rises to 155,000 deaths (Majowicz et al., 2010),
and 157,000 deaths are annually associated with ETEC only in
children from 28 days to 5 years of age (Bourgeois et al., 2016);
this represents, on the whole, a considerable burden in both
developing and developed countries.
It has largely been demonstrated that breast-feeding prevents
gastrointestinal diseases in infants and can also confer protection
from translocation of intestinal pathogens across the gut mucosa
(Wold and Adlerberth, 2000). However, lifestyle in developed
countries is leading to a drastic decrease in breast-feeding and,
although milk formulae have been very much improved during
the last few decades, they are still far from emulating the
multitude of biological functions of mother’s milk.
There are well-documented benefits of administering
probiotic microorganisms in milk formulas which include
improvements in several infections, allergic disorders, diarrhea,
and inflammatory diseases (Bin-Nun et al., 2005; Minocha,
2009). Furthermore, probiotics and their metabolites have
been suggested to have an important role in the formation
or establishment of a well-balanced, indigenous intestinal
microbiota in new-born infants, and adults (Gill, 2003; Salazar
et al., 2009) and to be remarkably beneficial in improving
microbiota in hospitalized pre-term infants (Schwiertz et al.,
2003).
In relation to the efficacy of probiotics to fight infectious
diseases, various probiotic strains, mainly from the Lactobacillus
spp. and Bifidobacterium spp. genus have demonstrated their
potential to inhibit or ameliorate the outcome of these infections
in humans and animal-models (Gill et al., 2001; Weizman et al.,
2005; Spinler et al., 2008; Tanner et al., 2016). In particular,
Bifidobacterium longum subsp. infantis CECT 7210, brand name
B. infantis IM1, which was isolated from infant feces, has
previously demonstrated a protective effect against rotavirus
infection in vitro and in a murine model (Moreno Muñoz et al.,
2011).
Pig in vivo models have usually been selected as an excellent
animal model to study various microbial infectious diseases
due to its greatest similarity to humans in terms of anatomy,
genetics, and physiology (Meurens et al., 2012). Moreover, the
domestic pig is susceptible, like humans, to ETEC and non-
typhoidal Salmonella enteritidis serovars such as Typhimurium
and Enteritidis, as these pathogens have broad host specificity
(Blanco et al., 1991; Gal-Mor et al., 2014).
The objective of this work is, therefore, to demonstrate the
potential of a probiotic strain, B. longum subsp. infantis CECT
7210, to enhance gut health at early-life stages and to fight
diarrhea-related diseases caused by ETEC K88 or Salmonella by
using the weaning piglet as a model.
MATERIALS AND METHODS
Two different experiments were performed to evaluate efficacy
of the probiotic against an oral challenge with Samonella
Typhimurium (Trial 1) or ETEC K88 (Trial 2). Both trials
were performed at the Experimental Unit of the Universitat
Autònoma de Barcelona (UAB) and received prior approval
(permit no. CEAAH1619) from the Animal and Human
Experimental Ethical Committee of this institution. The
treatment, management, housing, husbandry and slaughtering
conditions conformed to the European Union Guideline
(Directive 2010/63/EU)1.
Animals, Housing, and Experimental
Design
The two trials were conducted as a Level 2 High-Risk Biosecurity
Procedure, with appropriate training of the personnel involved.
A total of 144 male piglets were used: 72 LargeWhite× Landrace
piglets weaned at 24 (±4) days of age and 7.9 (±0.05) kg body
weight (BW) for the first trial and 72 Landrace piglets weaned at
21 (±2) days of age and 6.8 (±0.19) kg BW for the second. In both
cases, animals were obtained from high-sanitary-status farms, in
the first trial from mothers serologically negative to Salmonella,
and, in the second trial, from mothers that did not receive any
E. coli vaccination.
The UAB facilities available for these studies were an
experimental unit with three rooms of eight pens each (twenty-
four pens, three animals per pen). In each trial, animals were
distributed by taking initial BW into account for a similar average
BW within pens. The pens were allocated to four treatment
groups following an unbalanced 2 × 2 factorial arrangement
(factors being probiotic and pathogen challenge), with eight
replicates per treatment for the challenged animals and four
replicates for the non-challenged group. The treatments were,
therefore: (1) no challenge+ no probiotic (NN); (2) no challenge
+ probiotic (NP); (3) challenged + no probiotic (CN); and (4)
challenged + probiotic (CP). Two rooms were challenged with
pathogens and one was left unchallenged. In each room, probiotic
treatment was distributed within four pens on one side of the
room, and the four control pens were on the other side of the
room, separated by a corridor in between.
Pigs were maintained under a 14:30 h light/ 9:30 h dark
lighting regimen. Each pen (2 m2) had a feeder and a water
nipple to provide feed and water for ad libitum consumption. The
weaning rooms were equipped with automatic heating, forced
ventilation, and an individual heat-light per pen. The trials were
conducted during the spring season (March for the first trial and
May for the second), with an average room temperature of 26◦C
(± 4◦C).
Probiotic Strain and Diets
The probiotic treatment was supplied by Ordesa S.L. and
consisted of a daily dosage (109 colony-forming units [cfu]) of
1Directive 2010/63/EU of the European Parliament and of the Council of 22
September 2010 on the protection of animals used for scientific purposes Official
Journal.
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B. longum subsp. infantis CECT 7210, which was supplemented
in a 2 mL solution, while the control group received a
solution of the same amount of carrier as placebo. During
the experimental period, pigs received the treatment orally
and individually, in a daily pattern using disposable syringes
without needle. The probiotic tested was a unique batch of
lyophilized bacteria, which was re-suspended every day no more
than 1 h prior to administration. A pre-starter diet without
additives (Supplementary Table ST.1) was formulated to satisfy
the nutrient requirement standards for pigs (NRC, 2012) and was
given in a mash form.
Salmonella and ETEC Strains
In the first trial, the bacterial strain used for the oral challenge was
a Salmonella Typhimurium var. Monophasic (formula: 4,5,12:i:-,
resistance profile: ACSSuT-Ge, Fagotype: U302) isolated from
a salmonellosis outbreak of fattening pigs in Spain (mainly
enteric and with sporadic septicemia), which was provided by the
Infectious Diseases Laboratory (Ref. 301/99) of the UAB. The oral
inoculum was prepared by 24 h incubation at 37◦C in buffered
peptone water (Oxoid; Hampshire, UK) and diluted (1:20) with
sterile phosphate buffered saline (PBS) (Sigma-Aldrich; Madrid,
Spain). Final concentrations of the inocula were 1 × 109 cfu/mL
for the first inoculation day and 3 × 109 cfu/mL for the
second day. Inocula concentrations were determined before the
inoculation by McFarland standards and were plated the same
day in order to check them by manual plate counting.
In the second trial, the bacterial strain of ETEC K88 used
(serotype O149:K91:H10 [K-88]/LT-I/STb) was isolated from a
colibacillosis outbreak in Spain (Blanco et al., 1997). It was
kindly donated by the Dr. Blanco E. coli Reference Laboratory,
Veterinary Faculty of Santiago de Compostela, Lugo (Reference
FV12048). The oral inocula were prepared by an overnight
incubation at 37◦C in Brain Heart Infusion broth (Oxoid;
Hampshire, England) with slow agitation (1 × g) in an orbital
incubator. For the first inoculation, the culture was given directly,
and for the second inoculation day, bacteria were concentrated
by centrifuging (2,000 × g, 10 min and 4◦C), and supernatant
was eliminated. Final concentration of the inocula was 9 × 108
cfu/mL for the first inoculation day and 8 × 109 cfu/mL for the
second day. Inocula concentrations were also determined before
the inoculation byMcFarland standards andwere plated the same
day for manual plate counting.
Experimental Procedure
The duration of the study was 16 days for the Salmonella Trial
and 14 days for the ETEC K88 Trial. After an adaptation period
of 7 days for Trial 1 or 4 days for Trial 2, the animals were
orally challenged with the pathogen. One animal of each pen was
euthanized on Days 4 and 8 post-inoculation (PI) in Trial 1 and
on Days 4 and 9 PI in Trial 2.
Fecal samples for microbiological analysis were obtained from
random animals at their arrival, and individual body weight and
pen feed consumption were registered during the adaptation
time. After the adaptation period, the pathogenic bacteria culture
was administered to the challenged group by oral gavage: two 2
mL doses (2× 109 and 6× 109 cfu) of Salmonella Typhimurium
on Days 8 and 10 in the first trial and two 6 mL doses (5 ×
109 and 5 × 1010 cfu) of ETEC K88 on Days 5 and 6 in the
second trial. The same amount of sterile broth was given to the
non-challenged animals. In order to ensure that the stomach
was full at the time of inoculation, and thus, facilitate bacterial
colonization. Feed withdrawal was performed at 21:00 h of the
previous day and provided again 15 min before inoculation.
From the first challenge onwards, animals were checked daily
for clinical signs to evaluate their status post-inoculation (i.e.,
dehydration, apathy, and fecal score), always by the same person.
Fecal score was measured using a scale: 1= solid and cloddy, 2=
soft with shape, 3 = very soft or viscous liquid and 4 = watery
or with blood. Rectal temperature was assessed with a digital
thermometer (Thermoval Rapid, Hartmann; Spain) on Days 1,
2, and 3 PI. Mortality rate was also registered, and no antibiotic
treatment was administered to any of the animals in the trials.
Body weight was recorded on Days 0, 4, and 8 PI (9 PI in the
case of ETEC K88), while feed consumption on Days 0, 1, 2, 4,
6, and 8 PI (9 PI in the case of ETEC K88). The average daily
gain (ADG), average daily feed intake (ADFI), and gain:feed ratio
(G:F) were calculated by pen.
For microbiological analysis, on the inoculation day (0 PI)
fecal samples were taken aseptically from 24 animals after
spontaneous defecation associated with the manipulation of the
animal or by digital stimulation. In the case of the Salmonella
trial, fecal samples were taken from the animal with the highest
initial BW of each pen (N = 24), while in the ETEC K88
challenge, fecal samples were obtained from the animal with the
medium body weight of each pen (N = 24). For the Salmonella
trial, additional fecal samples were collected on Days 1, 3, and 7
PI from the same animal.
On Days 4 and 8 PI (9 PI in the ETEC K88 challenge), one pig
per pen was euthanized. On Day 4 PI, the animal selected was the
one with the intermediate initial BW, while on Day 8/9 PI, the
heaviest was selected. Animals were euthanized and sequentially
sampled during the morning (between 08:00 and 12:00 h).
Prior to euthanasia, a 10 mL sample of blood was obtained by
venipuncture of the cranial vena cava using 10 mL tubes without
anticoagulant (Aquisel; Madrid, Spain). Immediately after blood
sampling, piglets received an intravenous, lethal injection of
sodium pentobarbital (200mg/kg BW;Dolethal, Vetoquinol S.A.;
Madrid, Spain). Once dead, the animals were bled, the abdomen
was immediately opened and the whole gastrointestinal tract
excised.
In the ETEC K88 trial, fecal samples were obtained directly
from the rectum for traditional microbiology. For both trials,
digesta (∼50mL) from the ileum and proximal colon (considered
to be 0.75m from the ileocecal junction) was collected
and homogenized. The pH of the contents was immediately
determined with a pH-meter calibrated on each day of use
(Crison 52–32 electrode, Net Interlab; Barcelona, Spain).
From colonic digesta various subsamples were taken for
different analysis. One aliquot was stored at −80◦C for ETEC
K88 quantification by qPCR. To determine the presence of the
probiotic in the gut, additional subsamples were taken. Bacterial
isolation was performed in these samples before storing at−80◦C
with Geniul commercial protocol (Terrassa, Spain). Briefly, 1 g
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of colonic content sample was weighed in a 15 mL Falcon
tube and diluted 1:10 with enriched Man Rogosa Sharpe (MRS)
broth (Oxoid; Madrid, Spain) + 0.25% cysteine (Sigma-Aldrich;
Madrid, Spain) + 2% Tween 80 (Sigma-Aldrich; Madrid, Spain).
Ten glass spheres (5 mm diameter) were added to the tube and
vortex (1 min) to homogenize the suspension. Two-hundred-
fifty microliters of the sample suspension were transferred to
an Eppendorf tube with 250µL of enriched MRS broth. Three
centrifugation (13,000 × g for 5 min at 4◦C) and re-suspension
(500µL of enriched MRS broth) steps were performed and,
finally, the bacterial pellet was re-suspended in 200µL of sterile
PBS and stored at−80◦C for DNA extraction.
A set of ileal and colonic digesta samples was also preserved in
a H2SO4 solution (3 mL of content plus 3 mL of 0.2 NH2SO4) for
ammonia (NH3) determination and was kept frozen at −20
◦C.
An additional ileal and colonic sample set (∼20 g) was also frozen
(−20◦C) until analyzed for short-chain fatty acids (SCFA) and
lactic acid.
Bacteria attached to the intestinal mucosa were also analyzed
in the ETECK88 trial. For that, 5-cm-long sections of distal ileum
were collected from each animal, washed thoroughly with sterile
PBS, opened longitudinally and scraped with a microscopy glass
slide to obtain the mucosa scraping.
For the histological study, 3-cm sections from the ileum were
removed, opened longitudinally, washed thoroughly with sterile
PBS and fixed by immersion in a 4% formaldehyde solution
(Carlo-Erba Reagents; Sabadell, Spain).
Blood samples were centrifuged (3,000× g for 15 min at 4◦C)
after 4 h refrigeration, and the serum obtained was divided into
different aliquots and stored at−20◦C.
Analytical Procedures
For Salmonella bacteria counts (Trial 1), all samples were
transferred (1:10) to buffered peptone water. Quantitative
assessment was made by seeding serial dilutions of the samples
10−2, 10−4, and 10−6 in Xylose-Lactose-Tergitol-4 plates
(Merck; Madrid, Spain). Randomly chosen positive isolates
were identified by means of the API20E system (Bio-Mérieux;
Barcelona, Spain). With this scheme, animals were given a level
as following: negative, for animals with no Salmonella growing at
102 dilutions (<103 cfu/g); low, for animals with counts from 103
to 104 cfu/g; medium, for animals with counts from 105 to 106
cfu/g, and high, for counts from 107 to 108 cfu/g.
For enterobacteria and coliform counts (Trial 2), samples were
serially diluted in Lactated Ringer’s Solution (Sigma-Aldrich;
Madrid, Spain) from 10−4 up to 10−8 and seeded in MacConkey
agar (Oxoid; Madrid, Spain) and eosin methylene blue agar
(Scharlab; Barcelona, Spain). The plates were incubated for 24 h
at 37◦C, and colonies were manually counted.
Moreover, in the second trial, E. coli K88 was quantified in
colonic digesta by real-time PCR (quantitative PCR [qPCR])
using SYBR green dye. DNA from colonic samples (∼250 mg)
was extracted and purified using the commercial QIAamp DNA
stool minikit (Qiagen; West Sussex, United Kingdom). The
recommended lysis temperature was increased to 90◦C, and a
posterior incubation step with lysozyme was added (10mg ×
mL−1, 37◦C, 30 min) in order to improve the bacterial cell
rupture. The DNA was eluted in 200 mL of Qiagen buffer AE
and stored at −80◦C until use. A SYBR green qPCR targeting
the gene coding the F4 fimbria of E. coli K88 was performed
according to the procedure described by Hermes et al. (2013).
Results are expressed as cfu/g of fresh matter (FM) and log of F4
gene copies/g FM.
For probiotic detection, DNA was extracted from previously
pre-treated colonic samples with a commercial kit v-DNA
reagent following the manufacturer’s instructions (Geniul;
Terrassa, Spain. Doc. Code 450000112). Briefly, samples were
re-suspended in 1 mL of v-DNA buffer and centrifuged (13,000
× g for 5 min at 4◦C). After that, incubation (90◦C, 10 min)
with 200µL of v-DNA reagent was performed in a shaking
incubator and finally DNA was suspended in 600µL of v-DNA
buffer. DNA obtained from pure cultures of the probiotic was
used for construction of the standard curves. Bacterial cultures
were grown overnight in anaerobiosis with MRS broth, and
serial 1:10 dilutions were performed in sterile MRS. DNA from
dilution −1 (7.5 × 107 cfu/mL) to −6 (7.5 × 102 cfu/mL)
was extracted with QIAamp DNA minikit (Qiagen) and used as
standard curve. For the qPCR, a strain-specific probe designed
for the 16s RNA gene was used ([6FAM]CCGGTTAGTCCTCTA
CCGTACGCAAGC[TAM]) (Sigma-Aldrich; Madrid, Spain) and
an amplicon of 234 bp was obtained by the following primers
(Forward: 5′-CGCCGGTGCCAGTCA-3′; Reverse 5′-CACAGC
GGGCAGATCGGTAT-3′) (Sigma-Aldrich; Madrid, Spain). The
master mix used was 5x Hot Firepol Probe qPCR Mix Plus (no
ROX) (Solis BioDyne; Tartu, Estonia) and reaction conditions for
amplification of DNAwere 95◦C for 15min and 45 cycles of 95◦C
for 15 s and 60◦C for 1 min. Real-time PCR was performed with
the ABI 7900 HT Sequence Detection System (PE Biosystems)
using optical-grade ninety-six-well plates. The minimum level of
detection was established in 3.3× 103 cfu/g of colonic sample.
The SCFA and lactic acid analyses were performed by gas
chromatography, after the samples were submitted to an acid-
base treatment followed by an ether extraction and derivatization
with N-(tertbutyldimethylsilyl)-N-methyl-trifluoroacetamide
(MBTSTFA) plus 1% tert-butyldimethylchlorosilane (TBDMCS)
agent, using the method of Richardson et al. (1989), modified by
Jensen et al. (1995).
The concentrations of NH3 were determined with the aid of
a gas-sensitive electrode (Hatch Co.; Colorado, USA) combined
with a digital voltmeter (Crison GLP 22, Crison Instruments,
S.A.; Barcelona, Spain). Three grams of acidified content were
diluted (1:2) with 0.16M NaOH, after homogenization samples
were centrifuged (1,500 × g) for 10min. The ammonia released
was measured in the supernatants as a different voltage in mV
according to a procedure previously described in Hermes et al.
(2009), which was adapted from Diebold et al. (2004).
Serum concentrations of Tumor Necrosis Factor-α (TNF-α)
were determined by Quantikine Porcine TNF-α kits (R&D
Systems; Minneapolis, USA) according to the manufacturer’s
instructions. Pig major acute-phase protein (Pig-MAP)
concentration was determined by a sandwich-type ELISA
(Pig MAP Kit ELISA, Pig CHAMP Pro Europe S.A.; Segovia,
Spain) as described in Saco et al. (2011). In the Salmonella
trial, serological antibodies of Salmonella were tested by ELISA
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Salmonella Herdcheck (Idexx; Hoofddorp, Netherlands) to
determine positive animals. Cut-off for positivity was established
in optic density ≥40%.
Tissue samples for morphological measures were dehydrated
and embedded in paraffin wax, sectioned 4-µm thickness
and stained with hematoxylin and eosin. Measurements of 10
different villus-crypt complexes per sample were performed with
a light microscope (BHS, Olympus; Barcelona Spain) using the
technique described in Nofrarías et al. (2006).
Chemical analyses of the diets, including dry matter (DM),
ash, crude protein and diethyl ether extract, were performed
according to Association of Official Agricultural Chemists
standard procedures (AOAC International, 1995). Neutral-
detergent fiber and acid-detergent fiber were determined
according to the method of Van Soest et al. (1991).
Statistical Analysis
Results from both trials are expressed as lsmeans with their
standard errors unless otherwise stated (microbiological counts
were transformed [log] for analysis). A two-way ANOVA was
used to examine the effect of the experimental challenge and
probiotic treatment, as well as the interaction between the two
(only included when significant). The general linear and mixed
models of SAS (SAS Institute, 1990; Cary, NC, USA) were used
to analyze the effect of experimental treatments as well as Fisher’s
exact test on microbiological data, to analyze the frequencies of
positive animals as contingency tables.
When treatment effects were established, treatment means
were separated using the probability-of-differences function
adjusted by Tukey–Kramer. The pen was considered the
experimental unit for analysis, and random effect was used to
account for variation between pens. The α-level used for the
determination of significance for all of the analysis was P = 0.05.
The statistical trend was also considered for P < 0.10.
RESULTS
In general, the trials proceeded as expected. Animals used in
both studies showed a good health status at the beginning of the
experiment. In the Salmonella trial, none of the animals seeded
Salmonella in feces on arrival, and serological analysis confirmed
that animals had not been exposed to Salmonella prior to the day
of inoculation, all being sero-negative during the whole trial. In
the second trial (ETEC K88), one death was registered in the CN
group on Day 4 (before the challenge). Death was attributed to
post-weaning stress, as the animal was the smallest pig of the pen
and had previously shown symptoms of apathy. No antibiotic
treatment was administered to any of the animals in the trial.
Probiotic Detection
The ability of the probiotic strain B. longum subsp. infantis CECT
7210 to colonize the gut was evaluated by analyzing the probiotic
strain by qPCR in the colonic content on Day 8/9 PI. The bacteria
was detected in 70% of the treated animals (2.66 × 105 cfu/g for
NP and 4.11 × 104 cfu/g for CP in Trial 1; 4.05 × 104 cfu/g for
NP and 5.57 × 104 cfu/g for CP in Trial 2) and in none of the
non-treated ones (NN and CN). Levels quantified were near the
detection limit of the method (established at 3.4× 103 cfu/g). No
significant differences were seen related to the challenge in the
number of positive animals or detected concentrations.
Animal Performance
Effects of the experimental treatments on BW, ADG, and ADFI
are shown in Table 1. The Salmonella challenge negatively
affected final BW, ADFI, and ADG in the post-challenge
period, while the ETEC K88 challenge did not significantly
modify any of those parameters. Probiotic treatment did not
show significant effects on the studied parameters despite an
interaction (P = 0.035) observed in the ETEC K88 trial for
ADFI during the adaptation period. Before the challenge, the
CP group unexpectedly showed a lower ADFI than did its
control (CN). Daily registers of ADFI during the post-challenge
period are shown in Figure 1. As seen before, the oral challenge
with Salmonella, but not the ETEC K88 challenge, promoted a
significant reduction in the intake. In both trials, a significant
interaction challenge x probiotic (P = 0.019 for Trial 1 and P =
0.020 for Trial 2) was recorded, the probiotic promoting a higher
feed intake in the non-challenged animals and a decrease in the
challenged ones.
Clinical Signs
Figure 2 shows the evolution of fecal consistency after the
challenge in both trials. Pathogen inoculation significantly
affected fecal scores, with more liquid feces in both trials (P
challenge <0.001). However, whereas the Salmonella challenge
promoted diarrhea with scores between 2 and 3, the ETEC
K88 challenge only promoted a slight fecal inconsistency, with
scores that were rarely above two. Moreover, there was a clear,
differenciated pattern response after the inculation day between
challenged and non-challenged animals, as in the Salmonella trial
the interaction between challenge and day was significant (P <
0.001), but the pattern was very similar in the ETEC K88 trial.
Regarding the probiotic treatment, no significant differences in
fecal consistency were found in any of the trials.
A moderate increment in rectal temperature was seen due to
the Salmonella challenge (39.3 ± 0.05◦C vs. 39.6 ± 0.04◦C, P =
0.005), while this increment was not significant in the ETEC K88
trial (38.9± 0.05◦C vs. 39.1± 0.06◦C, P= 0.180). No differences
were detected due to probiotic treatment.
Microbial Analysis
In the first trial, none of the animals seeded Salmonella on arrival,
and non-challenged piglets remained negative along the whole
study. Figure 3 shows the evolution of Salmonella counts along
the post-challenge period in the challenged group. Challenged
animals treated with probiotic had lower fecal excretions of
Salmonella on Day 3 PI (P = 0.043).
In the ETEC K88 trial, no significant differences were seen on
the arrival day or before the inoculation, in fecal enterobacteria
or coliform plate counts (data not shown). Table 2 shows the
microbiological analysis on Days 4 and 9 PI in feces and colon
digesta. No significant differences related to the experimental
treatments were found in enterobacteria or coliform plate
counts in feces. Nevertheless, the qPCR aiming to target the
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TABLE 1 | Animal performance in Salmonella and ETEC K88 trials.
Treatmentsa P-value
CN CP NN NP RSDb Challenge Probiotic Interaction
TRIAL 1: Salmonella
BWc (kg)
Initial 7.88 7.88 7.95 7.87 0.131 0.590 0.502 0.516
Final 9.77 9.44 10.91 11.15 0.645 <0.001 0.861 0.318
ADFId (g/d)
Pre-inoculatione 179 170 183 183 42.0 0.659 0.812 0.812
Post-inoculationf 353 330 458 513 70.0 <0.001 0.598 0.216
ADGg (g/d)
Pre-inoculatione 94 58 90 103 43.8 0.290 0.539 0.214
Post-inoculationf 156 145 288 345 62.0 <0.001 0.399 0.215
TRIAL 2: ETEC K88
BWc (kg)
Initial 6.80 6.77 6.72 6.78 0.553 0.883 0.973 0.855
Final 8.74 7.78 8.25 8.35 1.078 0.937 0.184 0.271
ADFId (g/d)
Pre-inoculatione 151 84 115 130 42.1 0.787 0.165 0.035
Post-inoculationf 283 231 270 278 75.3 0.610 0.510 0.378
ADG g (g/d)
Pre-inoculatione 36 –11 23 10 50.5 0.865 0.186 0.434
Post-inoculationf 200 119 163 173 76.3 0.808 0.294 0.183
aTreatments: CN, challenged + no probiotic; CP, challenged + probiotic; NN, no challenge + no probiotic; NP, no challenge + probiotic. bResidual standard deviation. cBody weight.
dAverage Daily Feed Intake. eExperimental days 0 to 7 for Trial 1 and 0 to 4 for Trial 2. fExperimental days 8 to 16 (0 to 8 PI) for Trial 1 and 5 to 14 (0 to 9 PI) for Trial 2. gAverage Daily
Gain. n = 8 for groups CN and CP, n = 4 for groups NN and NP.
inoculated ETEC K88 bacteria in colonic content did show an
increase of copy numbers of the F4 fimbria K88 gene in the
challenged groups on Day 4 PI (P = 0.029). These differences
were not maintained on Day 9 PI, when levels decreased in
the challenged group near the detection limit of the method
(log 3.974 gene copies/g). No differences were found related to
probiotic administration. Regarding the microbial plate counts
in the ileal scrapings, around 30% of the samples on Day 4 PI and
50% on Day 8 PI were below the minimum level of detection (105
cfu/g).When analyzing the frequencies of animals with countable
numbers of enterobacteria or coliforms in ileal scrapings by
main effects (challenge effect or probiotic effect, Figure 4), there
was a trend for a higher percentage of animals with countable
coliforms on Day 9 PI in the challenged group (P = 0.087), and
the probiotic trended to diminish the percentage of animals with
countable coliforms on Day 4 PI (P = 0.077). No interaction
effects were found.
Changes in Fermentative Activity
Table 3 shows the changes promoted by the experimental
treatments on the main colonic fermentation products of
both trials (ileal data and SCFA molar ratios can be seen
in supplementary material [Supplementary Table ST.2 and
Supplementary Figure SF.1]).
The Salmonella challenge increased ammonia concentration
in ileum on Day 4 PI (1.5 vs. 2.3 mmol/l; P = 0.033) and showed
a trend to increase it in the colon (P = 0.094 and P = 0.097
for Days 4 PI and 8 PI, respectively). No significant differences
related to the experimental treatments were detected in any of the
rest of ileal parameters analyzed (pH, SCFA, and lactic acid). In
colonic content, a significant decrease in the total concentration
of SCFA (P < 0.001) was seen with the challenge on Day 4 PI,
more pronounced in animals receiving the probiotic treatment
(P challenge × probiotic = 0.008). This pattern was also found
on Day 8 PI with numerical differences (P challenge × probiotic
= 0.131). Molar ratios of SCFA (See Supplementary Figure SF.1)
were not significantly modified by any of the treatments although
trends for interactions were seen on Day 4 PI for propionic acid
(P challenge x probiotic = 0.068) and butyric acid (P challenge
× probiotic = 0.092). In both cases, the molar proportions
in the challenged animals that received the probiotic remained
closer to the mean values registered for the non-challenge
animals.
In the ETEC K88 trial, pathogen inoculation significantly
affected ileal fermentation on Day 9 PI; pH was reduced (6.4
vs. 6.1, P < 0.001) while acetic acid and lactic acid (the main
fermentation products) tended to be increased (3.4 vs. 9.6
mmol/kg for acetic acid, P= 0.051 and 12.7 vs. 37.3 mmol/kg for
lactic acid, P = 0.076). In colonic digesta, ETEC K88 provoked
a numerical increase in pH (P = 0.103) on Day 4 PI, with an
increase in the molar ratio of propionic (25.8 vs. 29.0%; P =
0.015) and a decrease in branched-chain fatty acids (1.69 vs.
1.07%; P = 0.042). The probiotic administration significantly
increased ileal pH on Day 4 PI (6.32 vs. 6.18, P = 0.024) and also
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FIGURE 1 | Average daily feed intake of the post-inoculation period.
Experimental days 8 to 16 (0 to 8 PI) for Trial 1: Salmonella (A) and 5 to 14 (0
to 9 PI) for Trial 2: ETEC K88 (B). ATreatments: CN, challenged + no probiotic;
CP, challenged + probiotic; NN, no challenge + no probiotic; NP, no challenge
+ probiotic. n = 8 for groups CN and CP, n = 4 for groups NN and NP.
Interactions only included when significant.
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FIGURE 2 | Evolution of the mean fecal scores in the different
experimental groups during the post-challenge period. Experimental
days 8 to 16 (0 to 7 PI) for Trial 1: Salmonella (A) and 5 to 14 (0 to 8 PI) for Trial
2: ETEC K88 (B). ATreatments: CN, challenged + no probiotic; CP, challenged
+ probiotic; NN, no challenge + no probiotic; NP, no challenge + probiotic. n
= 8 for groups CN and CP, n = 4 for groups NN and NP. Interactions only
included when significant.
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FIGURE 3 | Number of animals in the different range levels of fecal excretion of Salmonella at 1, 3, and 7 days post-challenge (Negative 0–102 cfu/g,
Low 103–104 cfu/g, Medium 105–106 cfu/g, and High 107–108 cfu/g). CN, challenged + no probiotic; CP, challenged + probiotic. n = 8 for groups CN and CP.
trended to increase pH in the colon (5.91 vs. 6.00, P = 0.071).
Moreover, a trend to reduce ammonia concentration was also
seen with the probiotic on Day 4 PI in the colon (P = 0.093)
and on Day 9 PI in the ileum (1.07 vs. 0.79 mmol/L, P = 0.058).
Regarding changes in molar proportions with the probiotic,
a significant increase of the branched-chain fatty acids molar
percentage was seen with the probiotic treatment on Day 9 PI
(1.35 vs. 1.99%; P= 0.039). Different interactions were registered
on Day 4 PI. In the ileum, probiotic trended to decrease lactic
acid in challenged animals and to increase it in non-challenged
animals (P challenge × probiotic = 0.052). In colonic content,
the probiotic trended to increase the total SCFA concentration
only in the non-challenged animals (P challenge × probiotic
= 0.082) with increases in the acetic acid proportion in the
challenged animals and decreases in the non-challenged ones (P
challenge × probiotic = 0.017, See Supplementary Figure SF.1).
A contrary interaction was seen for molar ratios of propionic and
butyric acids (P challenge × probiotic = 0.099 and P = 0.056,
respectively).
Immune Response
Table 4 shows the serological concentrations of the acute-phase
proteins Pig-MAP and the pro-inflammatory cytokine TNF-α.
In the Salmonella trial, both indexes were significantly increased
by the challenge on Days 4 (P < 0.01) and 8 PI (P < 0.03),
while in the ETEC K88 trial only TNF-α responded to the
challenge on Day 4 PI (P = 0.003). The probiotic treatment did
not significantly modify any of the parameters, although in the
ETEC K88 trial a significant interaction (P = 0.022) was found
in Pig-Map values on Day 4 PI, when the probiotic treatment
increased this index in the challenged animals but decreased it
in non-challenged ones.
Intestinal Morphology
The histomorphological results of the ileum on Day 4 PI are
summarized in Table 5. Results for Day 8/9 PI are not shown
in the table. The Salmonella challenge caused a decrease in
villus height (P < 0.001), deeper crypt depth (P = 0.007), and
worse villus:crypt ratio (P < 0.001) on Day 4 PI. A significant
interactionwas seen onDay 8 PI in crypt depth that was increased
by the probiotic in the non-challenged animals and decreased in
the challenged ones (212, 240, 229, and 203 µmNN, NP, CN, and
CP, respectively; P = 0.017). Moreover, other trends for similar
interactions were seen in the villus:crypt ratio on Day 4 PI (P
= 0.107) and Day 8 PI (P = 0.091). The Salmonella challenge
increased intra-epithelial lymphocytes (IEL) both days PI (P =
0.042 for Day 4 PI and 1.71 vs. 2.18, P =0.046 for Day 8 PI)
and mitosis in crypts on Day 4 PI (0.29 vs. 0.43 cel/100 µm,
P = 0.035). Probiotic also had significant effects on Day 8 PI
when it increased IEL (1.80 vs. 2.09 cel/100 µm, P = 0.002)
and decreased goblet cells (GC) (1.31 vs. 1.05 cel/100 µm, P =
0.025).
In the ETEC K88 trial, the challenge tended to decrease the
villus:crypt ratio on Day 4 PI (P = 0.066), increased IEL both
days (P = 0.004 Day 4 PI and 2.08 vs. 2.49, P = 0.104 Day
9 PI) as well as GC on Day 9 PI (0.91 vs. 1.22 cel/ 100, P =
0.093). The probiotic treatment trended to increase IEL on Day
4 PI (P = 0.091), and an interaction was seen on Day 9 PI in
villus height (P = 0.017), and villus:crypt ratio (P = 0.006) with
lower values in CP and increased ones in NP. No differences
related to the experimental treatments were detected in
mitosis.
DISCUSSION
The aim of this study is to determine if the administration of the
probiotic strain B. longum subsp. infantis CECT 7210 is able to
enhance health at early life stages and, moreover, if it confers
protection against common opportunistic digestive pathogens
such as Salmonella Typhimurium or ETEC K88. To assess this
objective, the probiotic was tested in two different trials, one for
each pathogen, and a different clinical outcome was obtained
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TABLE 2 | Effects of ETEC K88 trial on the plate counts of total coliforms and enterobacteria in fecal samples (log cfu/g fresh matter [FM]) and F4 gene
copy numbers of E. coli K88 in colon digesta (log of F4 gene copies/g FM).
Treatmentsa P-value
CN CP NN NP RSDb Challenge Probiotic Interaction
FECES
Enterobacteria (cfu/gFM)
Day 4 PI 8.24 8.31 8.48 9.09 1.339 0.390 0.561 0.644
Day 9 PI 7.75 8.31 8.21 8.12 1.114 0.635 0.784 0.511
Total Coliforms (cfu/gFM)
Day 4 PI 8.13 7.83 8.26 8.15 1.009 0.613 0.639 0.824
Day 9 PI 7.5 7.89 8.21 8.08 1.064 0.345 0.787 0.581
COLON DIGESTA
E. coli K88 (log copies/gFM)
Day 4 PI 5.38 6.00 4.25 4.14 1.464 0.029 0.692 0.571
Day 9 PI 4.70 5.11 4.78 4.90 0.556 0.786 0.285 0.556
aTreatments: CN, challenged + no probiotic; CP, challenged + probiotic; NN, no challenge + no probiotic; NP, no challenge + probiotic. bResidual standard deviation. n = 8 for groups
CN and CP, n = 4 for groups NN and NP.
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FIGURE 4 | Percentage of animals in ETEC K88 trial with countable plate counts of enterobacteria or coliforms in ileal scrapings (>105 CFU/g). Main
effects: challenge (n = 16 for total challenged animals, n = 8 for total non-challenged animals) and probiotic (n = 12 for probiotic and control animals).
for each challenge. In the Salmonella trial, nearly all parameters
evaluated responded significantly to the challenge, with the
animals presenting clear clinical signs of acute self-limiting
diarrhea whereas, in the ETEC K88 challenge, effects were milder
and no severe cases were seen, the evaluated parameters being
weakly affected. Hence, at the end, we were able to test the
probiotic in a wide range of intestinal disease.
In relation to the ability of bifidobacteria to inhibit pathogens,
Shu et al. (2000, 2001) observed, in a piglet model, that
Bifidobacterium lactis conferred protection against E. coli and
Salmonella (among other intestinal pathogens). However, it did
not completely reduce the pathogenic colonization. In addition,
Knol et al. (2007) associated an increase of bifidobacteria with
reductions of the presence of clinically relevant pathogens in
formula-fed pre-term infants. These protective effects against
pathogens have mainly been attributed to a pluripotent
stimulatory effect on the immune system (Gill et al., 2001;
Medina et al., 2007; Takahashi et al., 2006), although some other
modes of action could explain their antimicrobial activity like the
production of organic acids (Saulnier et al., 2009), bacteriocines,
and bacteriocine-like substances (Cheikhyoussef et al., 2008), and
the capacity to inhibit the pathogenic adhesion to enterocytes or
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TABLE 3 | Colonic ammonia concentration and fermentation products for Days 4 and 8 post-inoculation (PI) in Salmonella and ETEC K88 trials.
Treatmentsa P-value
Days PI CN CP NN NP RSDb Challenge Probiotic Interaction
TRIAL 1: Salmonella
NH3(mmol/L) 4 12.44 10.46 9.34 7.3 4.051 0.094 0.271 0.987
8 12.5 12.49 10.19 7.03 5.165 0.097 0.488 0.489
SCFA (mmol/kg) 4 116.5 90.2 123.3 141.3 17.49 <0.001 0.587 0.008
8 142.3 129.9 131.5 142.1 16.95 0.925 0.905 0.131
Lactic acid (mmol/kg) 4 2.48 4.48 2.45 2.3 6.926 0.717 0.762 0.723
8 1.18 3.59 0.9 3.58 4.982 0.948 0.251 0.949
TRIAL 2: ETEC K88
NH3(mmol/L) 4 14.3 13.5 20.3 14.0 4.67 0.122 0.093 0.197
9 15.2 27.6 16.7 18.5 11.52 0.457 0.168 0.300
SCFA (mmol/kg) 4 130.7 124.2 113.9 130.4 14.57 0.409 0.435 0.082
9 147.3 142.0 123.5 136.0 22.00 0.133 0.711 0.363
Lactic acid (mmol/kg) 4 9.05 4.14 7.65 3.02 7.37 0.698 0.151 0.965
9 2.87 1.65 7.02 2.97 3.75 0.107 0.120 0.392
aTreatments: CN, challenged + no probiotic; CP, challenged + probiotic; NN, no challenge + no probiotic; NP, no challenge + probiotic. bResidual standard deviation. n = 8 for groups
CN and CP, n = 4 for groups NN and NP.
TABLE 4 | Effects on serum levels of pro-inflammatory cytokine TNF-α and acute-phase protein Pig-MAP on Days 4 and 8 post-inoculation in Salmonella
and ETEC K88 trials.
Treatmentsa P-value
Days PI CN CP NN NP RSDb Challenge Probiotic Interaction
TRIAL 1: Salmonella
Pig-Map (mg/ml) 4 1.65 2.57 0.87 0.74 0.907 0.003 0.326 0.194
8 1.33 1.68 0.80 0.64 0.762 0.027 0.788 0.449
TNF-α (pg/ml) 4 146.2 155.0 95.8 84.5 37.01 0.001 0.938 0.542
8 128.1 134.1 87.2 82.7 27.95 0.001 0.950 0.673
TRIAL 2: ETEC K88
Pig-Map (mg/ml) 4 0.80 a,b 0.92 a 0.87 a,b 0.67 b 0.147 0.163 0.551 0.022
9 0.84 1.14 0.77 0.75 0.599 0.379 0.603 0.539
TNF-α (pg/ml) 4 83.9 79.2 64.0 49.9 16.85 0.003 0.218 0.536
9 92.3 92.2 90.1 77.2 17.97 0.284 0.516 0.427
aTreatments: CN, challenged + no probiotic; CP, challenged + probiotic; NN, no challenge + no probiotic; NP, no challenge + probiotic. bResidual standard deviation. n = 8 for groups
CN and CP, n = 4 for groups NN and NP.
prevent bacterial translocation (Gagnon et al., 2004; Searle et al.,
2009).
In the in vivo study herein presented, the administration
of a single daily dose (109 cfu) of B. longum subsp. infantis
CECT 7210 was not able to fully prevent pathogen colonization.
Nevertheless, it was able to reduce pathogen loads, particularly
the load of Salmonella in the fecal content and the number of
animals with high numbers of coliforms attached to their ileal
mucosa.
The probiotic also showed some particularly beneficial effects
on the animals. A clear effect on intestinal immune function was
seen with an increase in ileal IEL in both challenges. It is well-
established that IEL have a relevant role in the gastrointestinal
immune system, playing an important role in the regulation
of the immune response (Ogra et al., 1994). In particular,
other immune effects have been described with the same strain.
(Moreno Muñoz et al., 2011) reported an increment of the IgA
antibody levels in feces by the inclusion of the probiotic in
a murine model and also increases in anti-inflammatory IL-
10 have been recorded (unpublished data). In addition, recent
works have reported the production of peptides with protease
activity by this strain, able to hydrolyze β-casein and produce
functional peptides with antirotaviral activity (Chenoll et al.,
2015, 2016).
Effects of the probiotic treatment on other parameters
evaluated in this study were variable, depending on whether
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TABLE 5 | Histological determinations in ileum on Day 4 PI in Salmonella and ETEC K88 trials.
Treatmentsa P-value
Day 4 PI CN CP NN NP RSDb Challenge Probiotic Interaction
TRIAL 1: Salmonella
Villus height (µm) 186 141 250 296 46.9 <0.001 0.992 0.361
Crypt depth (µm) 244 245 206 218 24.5 0.007 0.562 0.581
Ratio Villus:Crypt 0.78 0.58 1.22 1.37 0.242 <0.001 0.818 0.107
IELc (N◦ cel/100µm) 2.09 2.03 0.75 1.44 1.027 0.042 0.482 0.407
TRIAL 2: ETEC K88
Villus height (µm) 224 223 252 260 49.7 0.152 0.886 0.818
Crypt depth (µm) 205 213 187 207 20.7 0.194 0.144 0.504
Ratio Villus:Crypt 1.11 1.05 1.34 1.25 0.258 0.066 0.524 0.877
IELc (N◦ cel/100µm) 2.64 2.74 1.79 2.36 0.420 0.004 0.091 0.224
aTreatments: CN, challenged + no probiotic; CP, challenged + probiotic; NN, no challenge + no probiotic; NP, no challenge + probiotic. bResidual standard deviation. n = 8 for groups
CN and CP, n = 4 for groups NN and NP. c IEL= Villus intraepithelial lymphocytes.
animals were challenged or not, and should be analyzed
separately.
In general terms, the effects of the probiotic in weight gains
and feed intakes were scarce. Nevertheless, in both trials, during
the first week post-challenge, an interaction could be seen in the
ADFI, with enhanced feed consumption in the non-challenged
animals receiving probiotic and diminution in the challenged
ones. Moreover, at the end of the ETEC K88 trial, the challenged
animals receiving the probiotic showed almost 1 kg of BW
less than their counterparts, despite this difference not being
significant. This apparent worse performance of the challenged
animals with the probiotic could be explained in the ETEC K88
trial by a random, worse adaptation of the CP group to weaning,
as this group unexpectedly decreased their intakes during the
first week before the challenge. Nonetheless, this explanation
cannot be given for the Salmonella trial, which suggests a
differential effect of the probiotic in challenged or non-challenged
animals.
Regarding colonic fermentation, it could be observed in
both trials, on Day 4 PI, that animals treated with the
probiotic showed an increase in the SCFA concentrations if they
were not challenged, but if they were orally inoculated with
the pathogen, SCFA concentration was reduced. In addition,
a favorable fermentative environment was detected in non-
challenged animals receiving probiotic, with a tendency to
increase butyric acid but not in the challenged ones. Although
Bifidobacterium spp. are not butyrate producing bacteria, it has
been proposed that cross-feeding of lactate or acetate produced
by bifidobacteria can stimulate the formation of butyrate by other
bacteria within the gut community (Belenguer et al., 2006; Van
der Meulen et al., 2006; De Vuyst and Leroy, 2011). For instance,
Falony et al. (2006) co-cultured fermentations of B. longum and
two acetate-converting, butyrate-producing colonic bacteria with
oligofructose as the sole energy source and observed interspecies
interactions. Due to the high complexity of the colon ecosystem,
we could not evaluate this metabolic process in our in vivo
assay. Nevertheless, the higher presence of butyrate reported for
the NP group in both trials and the diminution of acetic acid
in the same animals registered in the ETEC K88 trial would
suggest a possible cross-feeding phenomenon present only in the
non-challenged animals. In the challenged animals, gut dysbiosis
caused by the challenge had probably disturbed all of these
microbial interactions so much that it precluded the probiotic
to promote butyrogenic effects. Moreover, histomorphological
findings reinforce this theory as probably a higher butyrate
presence in the NP group, being the preferred energy
source for the colonocyte and a potent differentiating agent
(Scheppach, 1994), contributed to the observed increase of the
villus:crypt ratio of the non-challenged animals treated with the
probiotic.
Furthermore, although statistical significance was only
achieved in the ETEC K88 trial, Pig-MAP also responded
differentially, with increases in the challenged animals receiving
probiotic and decreases in the non-challenged ones on Day
4 PI. In swine, Pig-MAP is a major acute-phase protein,
and higher serum concentrations have been related to acute
inflammatory processes and also to the extent of tissue injury,
expressing strong and protective responses to bacterial infections
(Piñeiro et al., 2009). As mentioned above, our strain has been
reported to have anti-inflammatory effects (Moreno Muñoz
et al., 2011), but no evidence of this effect was seen in the
CP group.
All of these results suggest that our probiotic interacted
differently in each situation. A better comprehension of these
interactions (such as gut health conditions, bacterial populations,
and their connections) could bring to light improved application
protocols to get over the inconsistent results reported nowadays
in scientific literature.
This possible differential behavior of a probiotic under a
disease condition is particularly relevant if we wish to use
the probiotic therapy to treat intestinal disease. It is not the
first case in scientific literature in which uncertainty regarding
probiotic use is reported, as it has been recorded that probiotics
can be useful in a healthy situation, but detrimental when
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the intestinal barrier is affected, especially if the patient is
in an immuno-compromised situation; which could lead to
bacterial translocation and sepsis (Liong, 2008). In humans,
these bacterial sepsis for probiotic treatments have been mainly
reported for Lactobacillus spp. and Bacillus spp., as reviewed by
Boyle et al. (2006) and Liong (2008) but recently bifidobacterial
sepsis have been recorded in preterm infants treated with
probiotic (Jenke et al., 2012; Bertelli et al., 2015; Zbinden et al.,
2015) and even in an elder man undergoing chemotherapy
treatment (Weber and Reynaud, 2015). Trevisi et al. (2008)
tried different concentrations of a Bifidobacterium animalis in
weaning piglets with and without a FOS-based prebiotic and
found a positive correlation of the B. animalis administration
and translocation in mesenteric lymph nodes when FOS was
supplemented. The authors speculated about the possibility of
an increase in other bacteria promoted by FOS that could
also be translocated and thus, contribute to the reported
results.
Regarding the safety of the probiotic strain tested in this
study, (Moreno Muñoz et al., 2011) tested a 109 cfu dose in
an acute ingestion study with immunosuppressed mice, and no
bacterial load of Bifidobacterium spp. was found in blood, liver,
spleen, or mesenteric lymph nodes. Bifidobacteria are generally
considered safe and a vast body of literature appeals to protection
exercised by these probiotics in avoiding pathogen translocation.
Nevertheless, we speculate that in our challenged animals, gut
dysbiosis caused by the bacterial challenge, in addition to the
weaning syndrome, might have led the probiotic to have a
detrimental effect despite the observed reductions in pathogen
loads. More research should be addressed to study any possible
effect of this probiotic on the barrier integrity and bacterial
translocation.
Finally, although the pig has been described as an excellent
model for humans (Meurens et al., 2012; Wang and Donovan,
2015), certain limitations of the model should be taken into
account when interpreting results. Firstly, the host-specific
nature of B. longum subsp. Infantis. This bacteria is one
of the first and most predominant gut colonizers in infants
(Underwood et al., 2015) but not in pigs. Moreover, it has
co-evolved with humans (Arboleya et al., 2016) and this
would explain why B. infantis grow better in the presence of
human-milk oligosaccharides than in lactose.When human-milk
oligosaccharides are present, B. infantis increases their adhesion
rate to intestinal cells and expression of selected cytokines
(Chichlowski et al., 2012). Secondly, gastrointestinal disorders
are multifactorial, and therefore it is difficult to fully emulate
them in controlled experimental conditions (Rossi et al., 2012).
A moderate-high controlled dose of a single intestinal pathogen
(even inmultiple doses as in our experiment) achieved significant
challenge effects (diarrhea, inflammation, histomorphological
affections...) and allowed us to test the probiotic in different
controlled ranges of intestinal affections. However, this way to be
exposed to the pathogen is quite different from what a natural
process would be, where a low and continuous exposure is
normally expected. Lastly, the way the probiotic is administered
can also determine differences in the response. In this study,
the probiotic was given in a single bolus every morning at the
peak of eating activity, aiming to ensure that piglets received
the stated concentration of viable bacteria and that the stomach
was full to favor probiotic viability. Nevertheless, the effects
could have been different if we had given the probiotic in a
continuous pattern, as it would be if added to a milk formula.
Considering that the pig is not the natural host for these bacteria,
the probiotic probably had few opportunities to persist in the
gastrointestinal tract. This could be the explanation for the
low numbers of probiotic cells found in the colon, considering
that the animals were sampled more than 24 h after the last
dose.
To sum up, various consistent effects of the probiotic
in both experiments were detected although a different
response pattern was seen between challenged and non-
challenged animals. The potential of the probiotic was
demonstrated by clearly producing a beneficial response in
non-challenged animals and by improving their post-weaning
situation. Nevertheless, the response of challenged animals
treated with probiotic was not always positive although the
probiotic consistently reduced the pathogen loads. More
in-depth investigation should be performed to better assess
the mechanisms for the different response patterns observed
and improve probiotic therapeutic protocols. Limitations in
the model must be considered when evaluating experiment
results and extrapolating the potential of the probiotic to
children.
CONCLUSIONS
The probiotic B. longum subsp. infantis CECT 7210 had
a positive effect against pathogens by reducing the fecal
excretion of Salmonella Typhimurium and the mucosal
colonization of coliforms in the ETEC K88 trial. In addition,
it produced a stimulation of the intestinal immune system
by increasing IEL. Different responses to the probiotic in
challenged and non-challenged animals were also recorded,
mainly in feed intake, SCFA concentrations, and the
villus:crypt ratio that would suggest a distinct effect of the
probiotic intervention, depending on the structure of the
microbiota and on the integrity of the intestinal barrier. More
research is needed for fully guarantee the safety and efficacy
of this strain for its use in children with gastrointestinal
disorders.
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